LOAME
SLN

Lombard Odier Asset Management (Europe)’s Silence Therapeutics SLN Stock Holding History

Lombard Odier Asset Management (Europe)’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,238,039
Closed -$48.3M – 295
2024
Q1 		$48.3M Sell
2,238,039
-1,374,838
-38% -$29.9M 2.91% 3
2023
Q4 		$62.8M Buy
3,612,877
+168,965
+5% +$1.9M 3.64% 2
2023
Q3 		$33.8M Buy
3,443,912
+28,552
+0.8% +$211K 1.73% 6
2023
Q2 		$18.8M Buy
3,415,360
+121,955
+4% +$736K 0.88% 38
2023
Q1 		$20.4M Buy
3,293,405
+75,205
+2% +$887K 1.01% 26
2022
Q4 		$49.1M Sell
3,218,200
-1,200
-0% -$15.7K 1.99% 9
2022
Q3 		$32.3M Buy
+3,219,400
New +$33.9M 1.68% 9
2022
Q2 		– Sell
-1,561,551
Closed -$29.7M – 262
2022
Q1 		$29.7M Buy
+1,561,551
New +$31.1M 1.14% 25

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Lombard Odier Asset Management (Europe)'s SLN Position: Q2 2024 in Review

Lombard Odier Asset Management (Europe) sold out of Silence Therapeutics (SLN) in Q2 2024, closing a stake of 2,238,039 shares — an estimated $48.3M sold.

Lombard Odier Asset Management (Europe) first reported a position in SLN in Q1 2022 and held it in 8 quarters. The position peaked at $62.8M in Q4 2023. 71 funds tracked by Wall St. Rank hold SLN as of Q2 2024.

  • Lombard Odier Asset Management (Europe) reported no remaining Silence Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Lombard Odier Asset Management (Europe) sold 2,238,039 Silence Therapeutics shares in Q2 2024, an estimated $48.3M.
  • Lombard Odier Asset Management (Europe) first reported a position in Silence Therapeutics in Q1 2022 and held it in 8 quarters.
  • Lombard Odier Asset Management (Europe)'s Silence Therapeutics position peaked at $62.8M in Q4 2023.
  • 71 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2024.

Based on Lombard Odier Asset Management (Europe)'s 13F filing for Q2 2024, filed 14 Aug 2024.